Pharmaxis Limited
(ASX:PXS) shares have been placed in a trading halt, pending a release to the market on the outcome of a clinical trial.
The pharmaceuticals company says it’s received the results of a clinical trial of its product Bronchitol, known as B305.
The group says the trial was large and the results need detailed analysis.
Pharmaxis last traded at 31.5 cents.
Pharmaxis booked a net loss of $20.7 million in the first half of fiscal 2013.
